Market Overview:
The Chronic Obstructive Pulmonary Disease Market is growing rapidly across the world. A major factor driving the growth of this market is the increasing prevalence of smoking among the adults. Moreover, growing pollution in the environment and increasing asthma patients are expected to also grow the COPD market. The global Chronic Obstructive Pulmonary Disease Market is expected to grow during the forecast period of 2016 and 2022 as per the latest report published by Market Research Future (MRFR).
Due to unhealthy and sedentary lifestyle of people, the number of people suffering from chronic and respiratory diseases are growing rapidly. Among these, diseases a highly common condition is COPD. The disease causes long-term problems in breathing and poor inflow. The major factors driving the chronic obstructive pulmonary disease Market is the increasing adult smoking population. Due to the proliferation of environmental pollution, the number of patients suffering from asthma is increasing as well. This, in turn, is driving the global Chronic Obstructive Pulmonary Disease Market.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6175
Competitive Landscape
The global chronic obstructive pulmonary disease market comprises various leading players like Pfizer Inc (U.S), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S), Novartis AG (Switzerland), GSK (U.K), Dr. Reddy’s Laboratories Ltd (India), AstraZeneca (U.K), Merck (U.S), and others.
April 8th, 2019, Researchers from the Nanyang Technological University discovered the information that a majority of patients with a certain chronic lung disease is highly allergic to dust mites and fungi. This would aid people with bronchiectasis by receiving treatment for the same and have their conditions ameliorated.
Market Segmentation
The global chronic obstructive pulmonary disease market segmentation is based in terms of type, medicines, region, and treatment.
By type, the market divides into chronic bronchitis and emphysema. Chronic bronchitis is chronic cough and emphysema is a lung-based condition that causes the breath shortness.
By medicines, the market includes oral steroids, combination inhalers, bronchodilators, phosphodiesterase-4 inhibitors, inhaled steroids, theophylline, and antibiotics. It is worth noting that the antibiotics are useful for tackling bacterial infections. A combination inhaler comprises of two medicines in one device. Bronchodilators are medications that dilate the bronchial tubes of the lung by relaxing the bronchial muscles. Oral steroids are the non-narcotic and powerful types of prescriptive medication.
By treatment, the market comprises of lung transplant, oxygen therapy, bullectomy, and others. Bullectomy is a surgical process that involves the removal of a bulla. The bulla is a dilated air space in situated in the lung parenchyma.
By region, the market covers North America, Europe, Asia Pacific, and the Middle East and Africa.
Regional Analysis
The global chronic obstructive pulmonary disease market covers the following key regions the Americas, Europe, Asia Pacific, and the Middle East & Africa.
In Americas, North America holds the bigger market over the South American market. This is due to advanced medical facilities and the rising pool of investment in this region. Among all the regional markets, North America holds the largest share and is expected to grow strikingly in the forthcoming years. The regional market is majorly contributed by the presence of developed nations like the US and Canada.
Due to reasons similar to that of Americas, the Western Europe region hold an upper hand over the Eastern Europe region in terms of market share. The Western Europe region is spearheaded by developing nations like Germany, Italy, France, Spain, and the United Kingdom (UK).
The Asia Pacific region is expected grow strikingly in the forecast period due to the high population density and the improving medical infrastructure in countries across this region. Asia Pacific is identified as the fastest growing market, wherein countries like Australia, Japan, China, India, South Korea, and others contribute significantly to the overall growth of the region.
The Middle East and Africa region is expected to attain meagre growth in the coming years due to poor and limited infrastructure and minimal investment in the healthcare industry. However, the growing prevalence of hookah smoking in Gulf nations has increased the COBD percentage in this region.
Access Full Report and TOC @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612